The role of probiotics in vaginal health

Zhaojun Mei¹ and Dandan Li²*

¹Luzhou Maternal and Child Health Hospital, Luzhou Second People’s Hospital, Luzhou, China, ²University of Chinese Academy of Sciences, Beijing, China

Probiotics have been widely used in the treatment of intestinal diseases, but the effect of probiotics on female reproductive tract health is still controversial. Lactobacillus is the most abundant microorganism in the vagina, which is related to the vaginal mucosal barrier. Lactobacillus adheres to the vaginal epithelium and can competitively antagonize the colonization of pathogens. The factors produced by Lactobacillus, such as bacteriocin and hydrogen peroxide (H₂O₂), can inhibit the growth of pathogenic microorganisms and maintain the low pH environment of the vagina. Probiotics play an important role in maintaining the stability of vaginal microenvironment, improving immune defense and blocking the progression of cervical cancer. We review the research progress of probiotics represented by Lactobacillus in gynecological diseases such as human papilloma virus (HPV) infection, bacterial vaginosis (BV) and Genitourinary Syndrome of Menopause (GSM), so as to provide basis for further exerting the role of probiotics in women’s health.

KEYWORDS
probiotic, vaginal health, human papilloma virus, lactobacillus, vaginal microenvironment

Introduction

Vaginal microenvironment is composed of normal flora in vagina, endocrine regulation and mucosal epithelial barrier (Saraf et al., 2021). There are many microbial colonization in the vagina of healthy women, among which Lactobacillus plays a major role (95%) (Ilhan et al., 2019). Based on the different species of specific Lactobacillus, it can be divided into five different community state types (CSTs). Among them, CST I, II, III and V are mainly L. crispatus, L. gasseri, L. iners and L. jensenii respectively, while CST IV is on the contrary (Borgogna et al., 2020; Langner et al., 2021). It is represented by the reduction of lactic acid bacteria and there are strictly anaerobic species, such as Gardnerella, Megasphaera and Prevotella. Among them, L. crispatus, L. gasseri and L. jensenii can produce lactic acid and H₂O₂, acidify the vaginal environment to pH < 4.5, and inhibit the growth of other viruses and bacteria (Anderson et al., 2014; Das et al., 2022). However, L. iners is considered to be a Lactobacillus in an excessive state (Pramanick et al., 2019). In addition, the metabolites produced by Lactobacillus can also stimulate the host to produce antimicrobial peptides and anti-inflammatory...
cytokines (Niu et al., 2017). Vaginal epithelial cells change periodically under the action of estrogen and progesterone. Glycogen produced in this process provides energy for the growth of *Lactobacillus*. *Lactobacillus* can also prevent invasive pathogens from adhering to vaginal epithelium through competitive rejection (Han and Ren, 2021).

Vaginal microecological balance is a dynamic process. Slight vaginal flora imbalance can be regulated by itself. Serious flora imbalance will lead to gynecological diseases (Chao et al., 2019; Zhang et al., 2021). It is well known that cervical cancer is a cancer associated with HPV. Many studies have proved that the composition of vaginal microorganisms is related to the development of high-risk HPV infection and cervical lesions (Mitra et al., 2015; Jang et al., 2017; Mitra et al., 2020). The abundance of BV related bacteria, such as *Gardnerella*, may also increase the risk of cervical lesions during HPV infection (Wei et al., 2020). When women enter menopause, due to the decrease of estrogen level, the content of glycogen in epithelial cells and the number of *Lactobacillus*, pathogenic bacteria are easy to invade and reproduce, resulting in senile vaginitis (Athanasiou et al., 2016). Probiotics are a kind of active microorganisms that colonize the human intestinal tract and reproductive tract and are beneficial to the host. A large number of studies have proved that oral probiotics can treat a variety of digestive system diseases. *Lactobacillus*, as the most dominant bacterial species in the vaginal microenvironment, can maintain or change the vaginal microecological balance (Laniewski et al., 2020; Piccioni et al., 2021). In this review, we focus on the role of probiotics in maintaining vaginal health in women.

**Probiotics and cervical cancer**

Cervical cancer is the first malignant tumor of female reproductive tract, and about 300,000 people die of cervical cancer every year (Jahanshahi et al., 2020; Kovachev, 2020). When infected with HPV, it can destroy the vaginal microecological balance, reduce the number of *Lactobacillus* and increase the adhesion and colonization of abnormal flora. This further leads to the up regulation of HPV protein expression, promotes the development of cervical intraepithelial neoplasia (CIN), and even leads to the occurrence of cervical cancer (Carty et al., 2019). Gao et al. (Gao et al., 2013) were the first to systematically evaluate the relationship between vaginal microbiota and HPV infection and found that vaginal bacterial diversity in HPV-positive women was more complex and the composition of vaginal microbiota was different. A study (DI Pierro et al., 2021) demonstrated for the first time that oral *Lactobacillus curvatus* can change the state of CST and increase HPV clearance. Persistent high-risk HPV infection and changes in cervical microenvironment promote the development of cervical precancerous lesions (Liu et al., 2020). *Lactobacillus* activates the immune system to inhibit the proliferation of malignant tumors by secreting various antitumor metabolites, including phosphorylated polysaccharides and extracellular polysaccharides. (Champer et al., 2018; Pournollahi et al., 2020). There is an important link between increasing probiotic intake and reducing cancer progression.

### Probiotics act directly on cervical cancer cells

As a kind of vaginal probiotics, *Lactobacillus* can not only acidify the vaginal environment, stabilize the vaginal flora and enhance the function of vaginal epithelial cells, but also kill cervical cancer cells. *Lactobacilli* adsorb and occupy the vaginal epithelium, preventing the adhesion of aggressive pathogenic bacteria that cause malignancies (Abdolalipour et al., 2020). *Lactobacillus* can inhibit cancer cell proliferation by secreting peptidoglycan and exopolysaccharides. Probiotics mainly enhance the immune process of the body, promote the production of cytokines, and inhibit the proliferation of monocytes. Recent studies have shown that probiotics such as *Lactobacillus casei* and *Lactobacillus rhamnosus* play an anticancer role by activating the maturation of NK cells and dendritic cells (Li et al., 2020; Kandati et al., 2022). *Lactobacillus* can also affect cellular and humoral immunity, promote the proliferation and differentiation of thymus derived cells, and further promote the immune recognition and proliferation of bone marrow-derived cells (Medina-Contreras et al., 2020). In addition, probiotic metabolites also have cytotoxic effects on cervical cancer cells. Wang et al. (Wang et al., 2019) found that the increase of *Lactobacillus* spp. was related to the decrease of the detection rate of high-risk subtype HPV infection, cervical intraepithelial neoplasia and cancer. Microbiota plays an increasingly important role in cancer and treatment (Xie et al., 2020). As a promising non chemotherapy alternative therapy, *Lactobacillus* has attracted extensive attention in restoring and maintaining normal vaginal flora and treating cervical cancer. As shown in Table 1, the effects of probiotics on cervical cancer cells are summarized.

### Probiotics reduce the side effects of radiotherapy for cervical cancers

Radiotherapy is one of the main methods for the treatment of cervical cancer, but there are many side effects, the most common of which is radiotherapy-induced diarrhea (RID), which brings a greater burden to patients (Hombrink et al., 2000; Jahanshahi et al., 2020). Probiotics have shown good effects in the treatment of digestive system diseases and can alleviate the adverse reactions caused by inflammation. Probiotics can be added to reduce the side effects of...
Table 1: Experimental studies of probiotics in cervical cancer.

| Probiotics                      | Sources            | Cell line | Results                                                                 | Ref.               |
|--------------------------------|--------------------|-----------|-------------------------------------------------------------------------|--------------------|
| Lactobacillus plantarum SBL    | Vaginal secretions | HeLa      | Lactobacillus can inhibit the activity of HeLa cells.                   | Nami et al., 2014  |
| Lactobacillus gasseri and      | Commercial         | HeLa      | Supernatant of Lactobacillus is cytotoxic to cervical cancer cells.      | Moteyaseli et al., 2013 |
| Lactobacillus crispatus        | probiotics         | HeLa      | L. gasseri inhibits HeLa cell proliferation and shows anti-inflammatory | Sungur et al., 2017 |
| Bifidobacterium adolescentis   | Fecal samples      | SiHa      | Bifidobacterium can inhibit the expression of E6 and E7 oncogenes in     | Cha et al., 2012   |
| VSL#3                          |                    |           | SiHa cells.                                                             |                    |
| Lactobacillus rhamnosus and     | Commercial         | HeLa      | Supernatants of these two Lactobacilli were cytotoxic to HeLa cells.    | Nouri et al., 2016 |
| Lactobacillus crispatus, L.    | Commercial         | Caski     | Supernant of Lactobacillus inhibits cervical cancer cells by regulating  | Wang et al., 2018  |
| jensenii, and L. gasseri       | probiotics         |           | HPV oncogenes and cell cycle related genes.                             |                    |
| Lactobacillus casei and         | Human breast milk  | HeLa      | Supernant of Lactobacillus inhibits HeLa cells by regulating the         | Riaz Rajoka et al., 2018 |
| Lactobacillus paracasei         | Laboratory culture | HeLa and  | expression of apoptotic genes.                                          | Li et al., 2017    |
| DM8909                         |                    | U14       |                                                                      |                    |
| Lactobacillus crispatus and     | Commercial         | HeLa      | Probiotic supernatant can inhibit the proliferation of HeLa cells by    | Moteyaseli et al., 2016 |
| Lactobacillus rhamnosus         | probiotics         |           | down regulating HPV oncogene.                                          |                    |

Radiotherapy for cervical cancer and enhance the antitumor effect. A study (Okawa et al., 1993) of 228 patients with stage IIIB cervical cancer showed that patients receiving probiotics as adjuvants had longer survival than patients receiving radiotherapy alone. In another meta-analysis (Qiu et al., 2019) comparing the incidence of probiotics in the prevention of diarrhea caused by cervical cancer radiation therapy, the probiotics group had a lower incidence of RIR, RR 0.61 (95% CI 0.46-0.81; P = 0.0007). Negi et al. (Negi et al., 2020) developed cisplatin and probiotic bioburden pessaries for the treatment of cervical cancer. Histopathological studies showed that the preparation was safe for local administration of cisplatin. More research, especially clinical trials, is needed to understand the specific mechanisms by which probiotics can alleviate the side effects of radiation therapy for cervical cancer. As shown in Table 2, the research of probiotics in preventing or reducing the adverse effects of cervical cancer treatment on gastrointestinal tract is summarized.

TABLE 2: Studies with the role of probiotics in the prevention of RID therapy for cervical cancer.

| Probiotics                      | Methods                                                                 | Findings                                                                 | Ref.               |
|--------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------|
| Lactobacillus acidophilus plus  | Patients who received cisplatin and pelvic radiotherapy were divided    | Probiotics reduced the incidence of RID and                              | Chitapanarux et al., 2010 |
| Bifidobacterium bifidum         | into a probiotic group and a placebo group.                             | improved stool consistency.                                             |                    |
| Lactobacillus acidophilus LA-5  | Patients were randomized to a probiotics group (containing 75 billion   | Probiotics reduced the incidence of diarrhea and grade 2 abdominal      | Linn et al., 2019   |
| plus Bifidobacterium animalis   | live freeze-dried bacteria) or a placebo group.                        | pain.                                                                   |                    |
| subsp VSL#3                     | Patients were assigned to either the high-potency probiotic              | Probistic treatment reduces grade 3-4 diarrhea and reduces the number of | Deza et al., 2007   |
|                                | preparation VSL#3 or placebo.                                           | bowel movements.                                                        |                    |
| Lactobacillus acidophilus LAC-361 | Patients were randomized between a placebo and either of two regiments  | Probiotics reduce radiation-induced grade 2-3-4 diarrhea.                | Demers et al., 2014 |
| and Bifidobacterium longum BB-536 | of double strain Bifidact(6) probiotics.                               | Probiotic intervention had a significant effect on stool consistency.    | Giralt et al., 2008 |
| Lactobacillus casei DN-114 001  | Patients were randomly assigned to a probiotic drink or placebo.        |                                                                      |                    |
by studies have proved that it is feasible to develop HPV application and is still in the stage of clinical trial. Many antibodies. At present, therapeutic vaccine has no clinical BLS-M07 increased the production of serum HPV16E7 specific patients. The results demonstrated that oral administration of BLS-M07 increased the production of serum HPV16E7 specific antibodies. At present, therapeutic vaccine has no clinical application and is still in the stage of clinical trial. Many studies have proved that it is feasible to develop HPV therapeutic vaccine by using engineering bacteria represented by Lactobacillus. Future research seems to focus more on the use of such bacteria.

Effects of probiotics on BV

Bacterial vaginosis (BV) is a mixed infectious diseases caused by the imbalance of normal flora in the vagina, which is characterized by the decrease of Lactobacillus and the increase of anaerobic bacteria, especially Gardnerella and Prevotella (Onderdonk et al., 2016; Bagnall and Rizzolo, 2017). The microbial community structure of BV is basically consistent with CST IV (Coleman and Gaydos, 2018). The traditional treatment method is to use metronidazole and other antibiotics. In fact, the recurrence rate of BV after oral metronidazole treatment is very high, and the systemic use of antibiotics has great side effects (Muzny et al., 2020). In this case, new treatment strategies help to improve treatment outcomes. The use of probiotics can improve vaginal flora, increase beneficial bacteria, reduce the number of harmful bacteria, and further maintain the stability of vaginal flora environment (Ling et al., 2013). Nowadays, there is increasing evidence that probiotics are effective in the treatment of BV. In a meta-analysis of 30 studies (Jeng et al., 2020), BV patients were followed up after treatment and found that probiotic intervention reduced the recurrence rate of vaginitis (OR = 0.27, 95% CI: 0.18-0.41, P<0.001), improve the cure rate of vaginitis (OR = 2.28, 95% CI: 1.20-4.32, P = 0.011). (Selis et al., 2021) proved through in vitro experiments that Lactobacillus plantarum Lp62 and its supernatant could significantly inhibit the growth of Gardnerella. In another meta-analysis of 18 studies (Liu and Yi, 2022) with 3-month follow-up, the combination of antibiotics and probiotics was found to significantly reduce the recurrence rate of BV compared with antibiotics alone. Inflammation is considered to be a predisposing factor for tumorigenesis and development. Experimental studies in humans and animals support the correlation between chronic inflammation and cancer. Chronic inflammation will increase the gene mutation rate, lead to cancer and promote tumor metastasis. Probiotics combined with antibiotics play an important role in the treatment of inflammation. As shown in Table 3, we summarize the clinical research on probiotic treatment of BV in recent years.

Effect of probiotics on GSM

GSM was previously known as vulvovaginal atrophy or atrophic vaginitis (Careto et al., 2017; Donders et al., 2019). When women reach perimenopause, ovarian function declines, resulting in lower estrogen levels. More than 50% of postmenopausal women will have a series of annoying symptoms, including vaginal dryness, pruritus, difficulty in sexual intercourse, urgency and increased frequency of urination, and urinary tract infection (Yoo et al., 2022). Especially after menopause, the decrease of Lactobacillus and the increase of other anaerobic bacteria (Gardnerella and Prevotella) make cervical cells prone to canceration. Currently approved treatment options for GSM include estrogen therapy and non estrogen therapy (Gambrell, 1986). Recent studies have found that probiotics combined with estrogen can alleviate the related symptoms caused by vulvovaginal atrophy. Petricevic and others (Petricevic et al., 2008) found in a randomized controlled study that oral probiotics (Lactobacillus rhamnosus Gr-1 and Lactobacillus reuteri RC-14) in postmenopausal women could significantly reduce Nugent score and improve GSM symptoms (P = 0.001). In a randomized clinical trial (Ribeiro et al., 2018), the effect of estrogen with or without probiotics on GSM was investigated. Compared with estrogen alone, estrogen combined with probiotics significantly improved GSM symptoms, mainly vaginal dryness and dyspareunia, and increased vaginal health scores. Lim (Lim et al., 2021) also found that the intestinal microbial composition changed after ovariectomy. After supplementing the new intestinal Lactobacillus strain to ovariectomized rats, it can significantly reduce the climacteric symptoms, and promote the integrity of the intestinal barrier by increasing the mRNA level of tight junction related markers. In addition to local use of estrogen, oral or vaginal use of probiotics in postmenopausal women is also very effective in reducing menopausal symptoms caused by GSM. This provides a new choice for improving the quality of life of postmenopausal women.

Vaginal microbial transplantation

Fecal microbiota transplantation (FMT) has attracted more and more attention in the treatment of other diseases such as digestive system diseases, and has also achieved remarkable results. There has also been a growing interest in vaginal microbial transplantation (VMT) in recent years (Korpela et al., 2020; Wang et al., 2021). One study (Chen et al., 2021) investigated the effect of VMT on vaginal dysbiosis by establishing a vaginal dysbiosis model. The results showed that VMT significantly reduced bacterial-induced
Probiotics | Methods | Results | Ref.
--- | --- | --- | ---
*Lactobacillus acidophilus* GLA-14 and *Lactobacillus rhamnosus* HN001 | Patients received metronidazole (500 mg, bid) for 7 days and were randomly assigned to concurrently receive probiotics plus lactoferrin or placebo (n=48). | Probiotic mixture combined with lactoferrin improved symptoms (vaginal discharge and itching), Nugent scores, and recurrence rates. | Russo et al., 2019
*Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 | Patients received oral metronidazole for 7 days, and probiotics and placebo for 30 days (n=125). | Combined use of probiotics and antibiotics improves BV cure rates. | Anukam et al., 2006
*Lactobacillus crispatus* LMG S-29995*, Lactobacillus brevis*, and *Lactobacillus acidophilus* | After completing metronidazole treatment, patients received probiotics and placebo, respectively (n=166). | Oral probiotics reduce the rate of BV recurrence and prolong the time to disease recurrence. | Reznichenko et al., 2020
*Lactobacillus rhamnosus* BMX 54 | After completing metronidazole treatment, patients received placebo and vaginal tablets containing probiotics, respectively (n=250). | Patients treated with probiotics had reduced BV recurrence rate and vaginal pH. | Recine et al., 2016
*Lactobacillus crispatus* LbV 88, *Lactobacillus gasseri* LbV 150N, *Lactobacillus jensenii* LbV 116 and *Lactobacillus rhamnosus* LbV96 | After completing metronidazole treatment, patients received placebo and yogurt with probiotics, respectively (n=36). | Yogurt with probiotics increases BV recovery rates and improves vaginal microbes. | Lue et al., 2018
*L. brevis* CD2, *L. salivarius* subsp. salicinii, and *L. plantarum* | Patients were randomized to receive probiotic vaginal tablets and vaginal pH tablets (n=64). | Probiotics improve BV cure rates and reduce vaginal cytokines IL-1β and IL-6. | Hemalatha et al., 2012
*Lactobacillus rhamnosus* GR-1 and *L. reuteri* RC-14 | Patients were treated with probiotics for 6 months and metronidazole for 10 days (n=65). | Supplementation with probiotics did not improve BV cure rates, but improved vaginal flora composition. | Hummelen et al., 2010
*L. brevis* (CD2), *L. salivarius* subsp. salicinii (FV2), and *L. plantarum* (FV9) | Patients received probiotic-containing vaginal tablets or placebo for 7 days (n=39). | Supplementation with probiotics can increase the cure rate of BV and improve the vaginal environment. | Mastromarino et al., 2009

Inflammation, as well as the enrichment of pro-inflammatory cytokines, and restored normal vaginal microbiota. Lev-Sagie et al. (Lev-Sagie et al., 2019) were the first to report the use of VMT from healthy donors as an alternative to the treatment of patients with BV. After 5–21 months of follow-up, patients who received VMT showed improved vaginal fluid appearance and reconstituted vaginal microbiota dominated by *Lactobacilli*. Huang et al. (Huang et al., 2021) transplanted the feces of female mice with intact and prolific ovaries into the feces of ovariec-tomized mice and found that vaginal epithelial atrophy was significantly reduced and intestinal flora was significantly altered. In contrast to the studies described above, in a randomized controlled trial (Wilson et al., 2021) the gut microbiota of infants born by caesarean section was assessed at 2 hours, 1 month and 3 months after oral administration of maternal vaginal microbes. The results showed that oral administration of maternal vaginal secretions did not alter the gut microbiota composition of early infants compared with oral placebo infants. The findings of this study question the value of vaginal vaccination.

**Conclusion**

There is an association between a highly diverse vaginal microbiota and female reproductive tract health. Probiotics play an important role in maintaining the health of the female reproductive tract, alleviating gynecological diseases, and enhancing the local immunity of the vagina. The use of probiotics or VMT intervention has a certain effect on preventing the progression of CIN, treating BV, and relieving symptoms related to senile vaginitis. The development of 16SrRNA sequencing technology can help to identify microbial markers and carry out personalized prevention and treatment of diseases. At present, the mechanism of action of probiotics in cervical cancer is not fully understood. In the future, it is necessary to conduct larger-scale clinical studies and longitudinal tracking. Combination immunotherapies and multi-omics analysis are also necessary to fully understand the relationship between host, vaginal microbes and disease.

**Author contributions**

ZM organized the literature. ZM and DL co-authored the article.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Park, Y. C., Ouy, Y. T., Sung, M. H., Park, H. G., Kim, T. J., Cho, C. H., et al. (2019). A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3. J Gynecol Oncol. 30 (6), e88. doi: 10.3802/jgo.2019.30.e88

Petircivic, L., Unger, F. M., Vriezen, H., and Kiss, H. (2008). Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal breast cancer patients. Eur. J Obstet Gynecol Reprod. Biol. 141 (1), 54–57. doi: 10.1016/j.ejogrb.2008.06.003

Piccion, A., Franza, L., Vaccaro, V., Saviano, A., Zanca, C., Candelli, M., et al. (2021). Microbiota and probiotics: The role of lsmolactobacillus reuteri in diverticulitis. Medicina (Kaunas) 57 (8), 802. doi: 10.3990/mc5708002

Pourmollazi, S., Barzegari, A., Farshab-Khalili, A., Nouri, M., Fattahi, A., Shahnazi, M., et al. (2020). Anticancer effect of bacteria on cervical cancer: Molecular aspects and therapeutic implications. Life Sci. 246, 117413. doi: 10.1016/j.lfs.2020.117413

Pramankick, R., Mayadeo, N., Warke, H., Begum, S., Aich, P., and Aranha, C. (2019). Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: Are they different from normal microbiota? Microb. Pathog. 134, 103599. doi: 10.1016/j.micpath.2019.103599

Qu, G., Yu, Y., Wang, Y., and Wang, X. (2019). The significance of probiotics in preventing radiotherapy-induced diarrhea in patients with cervical cancer: A systematic review and meta-analysis. Int. J. Surg. 65, 61–69. doi: 10.1016/j.ijssurg.2019.03.015

Recine, N., Palma, E., Domingo, L., Gorgi, M., Imperiale, L., Sassi, C., et al. (2016). Restoring vaginal microbiota: biological control of bacterial vaginosis: a prospective case-control study using lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch. Gynecol Obstet 293 (1), 101–107. doi: 10.1007/s00404-015-3810-2

Rzemienchko, H., Heny, N., Malik, V., Khrystynak, T., Tynna, Y., Filipiuk, I., et al. (2020). Oral intake of lactobacilli can be helpful in symptomatic bacterial vaginosis: A randomized clinical study. J Low Genit Tract Dis. 24 (3), 284–289. doi: 10.1097/j.lgt.0000000000001518

Riaz Rajoka, M. S., Zhao, H., Lu, Y., Lian, Z., Li, N., Hussain, N., et al. (2018). Anticancer potential against cervix cancer (HeLa) cell line of probiotic lactobacillus casei and lactobacillus paracasei strains isolated from human breast milk. Food Funct. 9 (5), 2705–2715. doi: 10.1039/c8fo00547e

Ribeiro, A. E., Monstero, N. E. S., Moraes, A. V. G., Costa-Paiva, L. H., and Pedro, A. O. (2018). Can the use of probiotics in association with isoflavone improve the symptoms of genitourinary syndrome of menopause? results from a randomized controlled trial. Menopause 26 (6), 643–652. doi: 10.1097/gme.0000000000001279

Russo, R., Karadja, E., and De Seta, F. (2019). Evidence-based mixture containing lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef. Microbiol. 10 (1), 19–26. doi: 10.1097/fmb.0000000000000075

Sarf, V. S., Sheikh, S. A., Ahmad, A., Gillette, P. M., Bokhari, H., and Javed, S. (2021). Vaginal microbiome: normalcy vs dysbiosis. Arch. Microbiol. 203 (7), 3793–3802. doi: 10.1007/s00203-021-02414-3

Selis, N. N., Oliveira, H. B. M., Souza, C. L. S., Almeida, J. B., Andrade, Y., Silva, L. S. C., et al. (2021). Lactobacillus plantarum Lp242 exerts probiotic effects against gardnerella vaginalis ATCC 49144 in vaginal infection. Lett. Appl. Microbiol. 73 (5), 579–589. doi: 10.1111/lam.13547

Sangar, T., Aslim, B., Karaaslan, C., and Aktas, B. (2017). Impact of exopolysaccharides (EPSs) of lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa). Anaerobe 47, 137–144. doi: 10.1016/j.anaerobe.2017.05.013

Taghinezhad, S. S., Keyhani, H., Bermúdez-Humari, L. G., Donders, G. G. G., Fu, X., and Mohseni, A. H. (2021). Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis. Cell Mol. Life Sci. 78 (4), 1191–1206. doi: 10.1007/s00018-020-03652-2

Wang, J., Li, Z., Ma, X., Du, J., Lai, Z., Cui, X., et al. (2021). Translocation of vaginal microbiota is involved in impairment and protection of uterine health. Nat. Commun. 12 (1), 4191. doi: 10.1038/s41467-021-24516-8

Wang, H., Ma, Y., Li, R., Chen, X., Wan, L., and Zhao, W. (2019). Associations of cervicovaginal lactobacilli with high-risk human papillomavirus infection, cervical intraepithelial neoplasia, and cancer: A systematic review and meta-analysis. J. Infect. Dis. 220 (8), 1243–1254. doi: 10.1093/infdis/jix325

Wang, K. D., Xu, D. J., Wang, B. Y., Yan, D. H., Lv, Z., and Su, J. R. (2018). Inhibitory effect of vaginal lactobacillus supernatants on cervical cancer cells. Probioticks Antimicrob. Proteins 10 (2), 236–242. doi: 10.1016/j.dilacs.2017.06.003

Wei, Z. T., Chen, H. L., Wang, C. F., Yang, G. L., Han, S. M., and Zhang, S. L. (2020). Depiction of vaginal microbiota in women with high-risk human papillomavirus infection. Front. Public Health 8. doi: 10.3389/fpubh.2020.587298

Mei and Li 10.3389/fcimb.2022.963868

Frontiers in Cellular and Infection Microbiology
Werner, J., Decarlo, C. A., Escott, N., Zehbe, I., and Ulanova, M. (2012). Expression of integrins and toll-like receptors in cervical cancer: effect of infectious agents. *Innate Immun.* 18 (1), 55–69. doi:10.1177/1753425910392934

Wilson, B. C., Butler É. M., Grigg, C. P., Derraik, J. G. B., Chiavaroli, V., Walker, N., et al. (2021). Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: A pilot randomised placebo-controlled trial. *EBioMedicine* 69, 103443. doi:10.1016/j.ebiom.2021.103443

Xie, Y., Feng, Y., Li, W., Zhan, F., Huang, G., Hu, H., et al. (2020). Revealing the disturbed vaginal microbiota caused by cervical cancer using high-throughput sequencing technology. *Front. Cell Infect. Microbiol.* 10. doi: 10.3389/fcimb.2020.538336

Yoo, S. H., Kim, K. R., and Park, N. J. (2022). Transitional cell metaplasia of the uterine cervix: A histopathological and immunohistochemical analysis suggesting a possible role of androgenic conversion during urothelial-like differentiation in peri/postmenopausal women. *Ann. Diagn. Pathol.* 56, 151839. doi: 10.1016/j.anndiagpath.2021.151839

Zhang, Z., Li, T., Zhang, D., Zeng, X., Bai, H., Bi, H., et al. (2021). Distinction between vaginal and cervical microbiota in high-risk human papilloma virus-infected women in China. *BMC Microbiol.* 21 (1), 90. doi: 10.1186/s12866-021-02152-y